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Background: After liver injury, the repair process comprises activation and proliferation of hepatic stellate cells
(HSCs), which produce extracellular matrix (ECM) proteins. Peroxisome proliferator-activated receptor beta/delta
(PPARβ/δ) is highly expressed in these cells, but its function in liver repair remains incompletely understood. This
study investigated whether activation of PPARβ/δ with the ligand GW501516 influenced the fibrotic response to
injury from chronic carbon tetrachloride (CCl4) treatment in mice. Wild type and PPARβ/δ-null mice were
treated with CCl4 alone or CCl4 co-administered with GW501516. To unveil mechanisms underlying the
PPARβ/δ-dependent effects, we analyzed the proliferative response of human LX-2 HSCs to GW501516 in the
presence or absence of PPARβ/δ.
Results: We found that GW501516 treatment enhanced the fibrotic response. Compared to the other experimental
groups, CCl4/GW501516-treated wild type mice exhibited increased expression of various profibrotic and
pro-inflammatory genes, such as those involved in extracellular matrix deposition and macrophage recruitment.
Importantly, compared to healthy liver, hepatic fibrotic tissues from alcoholic patients showed increased expression
of several PPAR target genes, including phosphoinositide-dependent kinase-1, transforming growth factor beta-1,
and monocyte chemoattractant protein-1. GW501516 stimulated HSC proliferation that caused enhanced fibrotic
and inflammatory responses, by increasing the phosphorylation of p38 and c-Jun N-terminal kinases through the
phosphoinositide-3 kinase/protein kinase-C alpha/beta mixed lineage kinase-3 pathway.
Conclusions: This study clarified the mechanism underlying GW501516-dependent promotion of hepatic repair by
stimulating proliferation of HSCs via the p38 and JNK MAPK pathways.
Keywords: Peroxisome proliferator-activated receptor β/δ, Inflammation, Fibrosis, Signaling pathways, ProliferationBackground
Chronic liver disease represents an important cause of
mortality and morbidity. Repeated and/or chronic injury
exacerbates wound healing and tissue remodeling pro-
cesses, leading to progressive fibrosis and, ultimately,
end-stage cirrhosis. Currently, the only effective treat-
ment for end-stage cirrhosis is liver transplantation [1].
Therefore, therapeutic interventions that block early
stage progression of hepatic fibrosis are important for* Correspondence: walter.wahli@unil.ch
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HSCs are stimulated by factors that promote prolifera-
tion and transition from a quiescent, lipid/vitamin A-
storing phenotype towards an activated, proliferative
myofibroblast-like phenotype. Activated HSCs synthesize
alpha-smooth muscle actin (α-SMA), various cytokines,
chemokines, growth factors, and fibroblastic cell mar-
kers. In addition, they produce abnormally high levels of
ECM proteins and remodeling factors, which eventually
results in matrix accumulation [2,3]. However, the sig-
naling pathways that regulate HSC proliferation in liver
fibrogenesis remain poorly defined. This makes it diffi-
cult to design antifibrotic agents.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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are ligand-inducible transcription factors of the nuclear
hormone receptor family, which have been associated
with liver fibrosis [4]. Distinct genes produce three
PPAR isotypes, PPARα (NR1C1), PPARβ/δ (NR1C2),
and PPARγ (NR1C3) [5]. PPARs are activated by a large
spectrum of endogenous fatty acids and eicosanoids
involved in metabolic and inflammatory pathways [5].
The synthetic PPARα ligand, clofibrate, protects against
CCl4-induced liver fibrosis [6]. PPARγ, activated by glita-
zones, down-regulates inflammation, collagen synthesis,
HSC activation and proliferation [7,8]. Previous studies
have shown that the PPARγ agonist ciglitazone dimin-
ished adult liver progenitor (oval) cell response and
decreased fibrosis in mice fed with a choline deficient,
methionine supplemented diet, while the PPARβ/δ ligand
GW501516 did not affect oval cell proliferation or liver
fibrosis in the same model [9]. Although PPARβ/δ is
highly expressed in HSCs, its function in fibrosis is still
debated. In cultured primary rat HSCs, the p38 mitogen-
activated protein kinase (MAPK) pathway up-regulated
PPARβ/δ expression during the transition into the active
phenotype. Furthermore, PPARβ/δ transcriptional activa-
tion by the selective synthetic ligand L165041 enhanced
proliferation of both quiescent and activated HSCs [10]
and PPARβ/δ modulated the expression of vitamin A
metabolism-related genes in HSCs undergoing activation
[11]. In rats, acute treatment with L165041 and CCl4
increased the expression of fibrotic markers [10]. In con-
trast, PPARβ/δ was protective against azoxymethane and
CCl4-induced hepatotoxicity and, when activated with
the synthetic ligand GW0742, down-regulated proinflam-
matory gene expression in CCl4-treated mice [12,13]. In
a model of chronic ethanol-fed rats, L165041 reduced
hepatic injury, oxidative stress and DNA damage, and
improved the regenerative response in livers [14]. A re-
cent study in mice also demonstrated hepatoprotective
and antifibrotic effect of the PPARβ/δ ligand KD3010 in
both CCl4-induced and cholestatic liver fibrosis, in con-
trast to GW501516 that had profibrogenic effects [15].
The effect of GW501516 was studied after short expos-
ure (12 days) to CCl4 and the molecular mechanism by
which GW501516 increased fibrosis was not investigated.
These different outcomes suggested that the action of
PPARβ/δ might be context-dependent, since the above-
mentioned studies included different PPARβ/δ ligands,
different rodent species and different models of liver
damage. Thus, the role of PPARβ/δ in liver injury
remains uncertain, and its signaling pathways for regulat-
ing liver fibrosis are unknown.
This study focused on the role of GW501516-activated
PPARβ/δ in mouse liver fibrosis after long-term CCl4
treatment, which is more relevant to liver diseases in
human [2,3]. The results presented below clarified themechanism by which GW501516-activated PPARβ/δ
enhanced HSC proliferation, and may facilitate the de-
velopment of therapeutic approaches to prevent the pro-
gression of liver fibrosis through antagonizing PPARβ/δ.
Results
GW501516-activated PPARβ/δ increased CCl4-induced
hepatic fibrosis
To study liver fibrosis, male wild type and PPARβ/δ-null
mice received intraperitoneal injections of CCl4 twice per
week for 6 weeks. The effect of activated PPARβ/δ on liver
fibrosis was assessed by treating mice with the well-
characterized selective ligand GW501516, in addition to
CCl4. CCl4-treated wild type and PPARβ/δ-null mice devel-
oped moderate, centrolobular necrosis with inflammatory,
periportal, neutrophil and Kupffer cell/macrophage infiltra-
tion. Calcium deposits were found in the necrotic areas
(not shown). Liver pathology was slightly more developed
in CCl4-treated wild type compare to PPARβ/δ-null mice
(Figure 1A). This indicated that, in the absence of exogen-
ous activation, PPARβ/δ did only moderately impact liver
fibrosis. However, wild type mice co-treated with CCl4/
GW501516 showed more severe centrolobular necrosis,
marked neutrophil infiltration, and degenerated neutrophils
and macrophages, including Kupffer cells. This result
correlated with serum alanine aminotransferase (ALT)
levels and liver weight (Figure 1B). These effects were
not observed in similarly treated PPARβ/δ-null mice,
which suggested that the GW501516 effect was
dependent on PPARβ/δ expression. The expression pro-
files of Pparα and Pparγ under the different experimental
conditions were similar in PPARβ/δ-null mice and wild
type mice (Additional file 1: Figure S1). This indicated
that PPARβ/δ deletion probably did not trigger compen-
satory effects. Nonetheless, it is worth noting that CCl4
treatment reduced the expression of Pparα and Pparγ
by more than 50%.
Next, because CCl4 is known to impact hepatic lipid
homeostasis, we tested the distribution of neutral lipids
[16]. The total triglycerides increased with CCl4, and
even more with CCl4/GW501516 co-treatment in wild
type mice, whereas the different treatments did not sig-
nificantly affect triglyceride levels in PPARβ/δ-null mice
(Figure 1C). The higher levels of triglycerides in the
livers of CCl4-treated wild type compared PPARβ/δ-null
mice may indicate a moderate contribution of PPARβ/δ
in the wild type animal, consistent with the liver path-
ology described above. On the contrary, neither treat-
ment affected the levels of total free cholesterol or
cholesterol esters in wild type or PPARβ/δ-null mice.
The mechanisms underlying this PPARβ/δ-dependent
accumulation of triglycerides, which triggered hepatic
steatosis in co-treated wild type mice, is in accordance
with marked fibrosis but remain to be explored.
Figure 1 Effect of GW501516-activated PPARβ/δ on CCl4-induced liver fibrosis and PPARβ/δ target gene expression. A) Mouse liver
sections stained with hematoxylin/eosin after 6 weeks without (CTRL, vehicle) or with CCl4 or CCl4/GW501516 co-treatment. CTRL: controls treated
with 0.5% CMC. Note that olive oil as control gave similar results. WT, wild type mice; KO, PPARβ/δ-null mice. Scale bar: 100 μm. B) Serum alanine
aminotransferase levels (left) and liver weight (right) at different treatments. C) Total hepatic triglycerides (left), total free cholesterol (middle) and
cholesterol esters (right) levels with different treatments were determined by gas chromatography. Control mice were treated with olive oil. D)
qRT-PCR analysis shows expression of (left) Pparβ/δ and two of its target genes, (middle) Pdk4 and (right) Plin2, in mice treated as indicated. WT,
wild type mice; KO, PPARβ/δ-null mice; ND, not detected. Means ± SEM (n=6). * = p<0.05, ** = p<0.01, Student's t-test.
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Pparβ/δ expression in wild type mice. Importantly, the
expression of pyruvate dehydrogenase kinase-4 (Pdk4)
and Perilipin 2 (Plin2), two target genes of PPARβ/δ were
also increased in wild type mice, which indicated tran-
scriptional activation (Figure 1D). Note that GW501516
alone stimulated the expression of Pdk4 and Plin2 in wild
type but not PPARβ/δ-null mice (not shown), while CCl4alone also stimulated the expression of Pdk4 in both wild
type and PPARβ/δ-null mice and Plin2 in wild type mice,
but the stimulation was highest in wild type co-treated mice.
Collectively, these results provided evidence that
GW501516-dependent PPARβ/δ activity was enhanced in
hepatic fibrotic tissues. This suggested that in this model,
PPARβ/δ might exacerbate uncontrolled liver repair. This
is consistent with the profibrotic effect of GW501516
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null mice [15].
GW501516-activated PPARβ/δ increased expression of
pro-inflammatory markers and macrophage infiltration
in fibrotic livers
In liver sections from untreated wild type and PPARβ/δ-
null mice, F4/80 staining (macrophages, Kupffer cells)Figure 2 Ligand-activated PPARβ/δ triggered hepatic macrophage inf
were immunostained with an antibody against the F4/80 macrophage mar
were obtained from mice treated without (CTRL; 0.5% CMC; note that olive
GW501516 for 6 weeks. Eight livers were analyzed for each treatment; one
KO = PPARβ/δ-null mice. B) qRT-PCR analysis shows mRNA expression of M
of triplicate assays (n=6). C) MIP-1α and MCP-1 protein levels determined fr
treatments. WT = wild type; KO = PPARβ/δ-null mice. Means ± SEM of triplwas weak (Figure 2A). However, in CCl4-injured livers,
we measured an important increase in staining, whereas
the number and localization of recruited macrophages/
Kupffer cells were similar in both genotypes. Most of the
damage was located around blood vessels. Administra-
tion of GW501516 alone doubled the number of infil-
trated macrophages/Kupffer cells in the wild type mice,
but not in PPARβ/δ-null mice (not shown).iltration and inflammatory marker production. A) Liver sections
ker (brown). Nuclei were counterstained with eosin (blue). Liver tissues
oil as control gave similar results) or with CCl4 alone or both CCl4/
representative example is shown. Scale bar: 100 μm. WT = wild type;
ip-1α, Mcp-1, Pdgfbb, Tnf-α, Tgfβ1 and F4/80. Results are means ± SEM
om whole cell protein extracts isolated from livers after the indicated
icate assays (n=6). * = p<0.05; Student's t-test.
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damaged wild type livers presented high levels of the pro-
inflammatory markers such as macrophage inflammatory
protein-1α (Mip-1α), monocyte chemoattractant protein-1
(Mcp-1), platelet-derived growth factor BB (Pdgfbb),
tumor necrosis factor alpha (Tnf-α), transforming growth
factor beta 1 (Tgfβ1) and the mouse homolog (F4/80) of
the EGF-like module-containing mucin-like hormone
receptor-like 1 in wild type mice (Figure 2B), which are
known to be expressed in activated HSCs, infiltrated Kupf-
fer cells, and other immune cells. Treatment with CCl4
alone also induced the mRNA levels of these markers, but
to a lower extent and in a PPARβ/δ-independent manner
(Figure 2B). This was confirmed at the protein level for
MIP-1α and MCP-1 (Figure 2C). Thus, GW501516-
activated PPARβ/δ in fibrotic liver increased inflammation,
most likely as a consequence of increased immune cell
infiltration and HSC activation and proliferation.
GW501516-activated PPARβ/δ increased ECM deposition
during fibrosis
Fibrosis is characterized by the deposition of ECM com-
ponents. They are secreted by activated HSCs during
liver repair. Histological sections stained with Sirus redFigure 3 Ligand activated PPARβ/δ-dependent increase in hepatic pr
in liver sections from wild type (WT; top row) and PPARβ/δ-null mice (KO; bott
control gave similar results) or treated with CCl4 or CCl4/GW501516 for 6 week
label fibrin in WT and KO mice treated with CCl4/GW501516. Sections are repre
PCR analysis shows pro-Col1α1 (left) and pro-Col3α1 (right) mRNA expression af
Results are means ± SD of at least three independent experiments performedshowed normal distributions of collagen around liver
blood vessels in untreated wild type and PPARβ/δ-null
groups (Figure 3A). CCl4 treatment caused a moderate
increase in perilobular and centrolobular collagen distri-
butions, widespread pericellular fibrosis, and centro-
central fibrotic septa, which was more important in wild
type compared to PPARβ/δ-null livers as determined by
staining quantification (Additional file 1: Figure S2). The
damages were graded with an Ischak’s score of 2 in most
liver sections. Co-administration of GW501516 and
CCl4 strongly enhanced collagen deposition at the cen-
trolobular and periportal regions, and collagen fibers
extended within the lobule and out to the surrounding
hepatocytes in wild type mice, but not in similarly-
treated PPARβ/δ-null mice. In wild type mice, CCl4/
GW501516 caused hepatic damage with an Ischak’s score
of 3 in most liver sections. This result was supported by
quantification of the Sirus Red staining (Additional file 1:
Figure S2) and by staining for fibrin with Martius/Scar-
let/Blue (MSB) (Figure 3A right panels). These results
showed that GW501516-activated PPARβ/δ in CCl4-
injured livers enhanced collagen deposition and thus,
promoted fibrosis; however, this effect was not observed
in PPARβ/δ-null mice.o-fibrogenic marker expression. A) Sirus red staining of collagen fibers
om row). Mice were untreated (CTRL; 0.5% CMC; note that olive oil as
s. The far right panels are the samples stained with Martius/Scarlet/Blue to
sentative of six mice in each treatment group. Scale bar: 100 μm. B) qRT-
ter 6 weeks of the indicated treatments in WT and PPARβ/δ KO mice.
in triplicate (* = p<0.05, Student's t-test).
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increased pro-Col1α1 and pro-Col3α1 mRNA expression
in both wild type and PPARβ/δ-null genotypes, though
to a slightly lesser extent in the latter (Figure 3B), in
agreement with the Sirus Red staining (Additional file 1:
Figure S2). Interestingly, the combined CCl4/GW501516
treatment further induced the expression of these genes
compared to CCl4 alone only in wild type mice.
Taken together, our observations showed that activa-
tion of PPARβ/δ in CCl4-injured livers strongly promoted
collagen deposition, a hallmark of liver fibrosis.
GW501516-activated PPARβ/δ exacerbated HSC activation
and proliferation
During fibrogenesis, HSCs proliferate and transdifferenti-
ate to myofibroblasts that express α-SMA [1]. Immuno-
histochemistry with α-SMA and Ki67 antibodies showedFigure 4 PPARβ/δ induced HSC proliferation in fibrotic mouse liver. A
against Ki67 (proliferation marker, red) and α-SMA(activated HSC marker, gr
CCl4 or CCl4/GW501516 for 6 weeks. Sections are representative of 6 mice
Desmin and α-SMA mRNA expression after 6 weeks of the indicated treatm
triplicate experiments (n=6). * = p<0.05, Student's t-test.a quasi absence of staining in untreated wild type and
PPARβ/δ-null liver sections (not shown). After chronic
CCl4 exposure, many α-SMA and Ki67 positive cells were
observed within the lobule and in the fibrotic septa, at
slightly higher levels in wild type compared to PPARβ/δ-
null mice (Figure 4A). These results indicated that CCl4
treatment induced the activation and proliferation of
HSCs. Administration of GW501516 to CCl4-injured
livers further increased the lobular distribution and the
number of activated and proliferative HSCs only in wild
type mice. Since GW501516 alone had no effect on HSC
proliferation in absence of CCl4 treatment in wild type
mice (not shown), this implied that CCl4 activation of the
HSCs was a prerequisite for the PPARβ/δ-dependent ef-
fect on cell proliferation.
Consistent with these results, CCl4 administration
increased the levels of α-Sma mRNA by 2-fold in both) Mouse liver sections were double-immunostained with antibodies
een). Nuclei were stained with DAPI (blue). Mice were treated with
in each treatment group. Scale bar: 100 μm. B) qRT-PCR analysis shows
ents in wild type and PPARβ/δ KO mice. Results are means ± SEM of
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administration of GW501516 and CCl4 strongly
increased the expression of both Desmin and α-Sma
transcripts in wild type mice, but not in PPARβ/δ-null
mice. This suggested that the agonist action was PPARβ/
δ-dependent. These results demonstrated that ligand-
activated PPARβ/δ increased the proliferation of acti-
vated HSCs in CCl4-injured mouse liver, a cellular
process that promotes and amplifies fibrosis.
PPARβ/δ increased LX-2 cell proliferation through p38 and
SAPK/JNK MAPKs via upstream PI3K activation
The molecular mechanisms underlying PPARβ/δ regula-
tion of activated HSC proliferation after liver injury are
not known. To address this question, we first explored
whether treatment with GW501516 also impacted gene
expression in human activated HSC LX-2 cells, which
express key genes for hepatic fibrosis and are phenotyp-
ically similar to primary activated human HSCs in vivo
[17]. These cells are in a pre-activated state and they
progressively express activation markers after cultivation
[18]. Therefore, they present some similarity with CCl4
activated HSCs. The results presented in Figure 5 showed
that the expression of genes stimulated in the mouse liver
after CCl4/GW501516 treatment (see Figure 1–4) was also
enhanced by GW501516 in human HSC LX-2 cells. This
observation prompted us to use these cells to identify the
signaling pathways involved in HSC proliferation. For this
purpose, we stably knocked down (KD) PPARβ/δ in
human LX-2 stellate cells with lentiviral constructs that
contained short interfering RNAs (siRNAs) against
PPARβ/δ mRNA. This resulted in a 90% reduction in
PPARβ/δ mRNA expression (Figure 6A).
The proliferation of LX-2 cells was measured in a [3H-
methyl]-thymidine incorporation assay. Treatment with
GW501516 increased proliferation by 2.5 fold compared
to control DMSO-treated cells. This effect was blunted in
PPARβ/δ KD LX-2 cells (Figure 6B). To elucidate the cas-
cade of events between activated PPARβ/δ and increased
LX-2 cell proliferation, we specifically inhibited several
signaling pathways that might be involved in activated
HSC proliferation. The MAPK extracellular signal-
regulated kinase 1/2 (Erk1/2) pathway inhibitor, PD98049
(MEK1 inhibitor), had no effect on GW501516-inducible
LX-2 cell proliferation (Figure 6C). In contrast, pre-
incubation with the PI3K pathway inhibitor, LY294002,
followed by exposure to GW501516 for 48 h inhibited
PPARβ/δ-dependent LX-2 cell proliferation at the dose of
100 nM (Figure 6D). This implicated a PI3K-dependent
pathway in GW501516-induced HSC proliferation. Next,
we applied inhibitors of two PI3K downstream targets, the
stress-activated protein kinase/c-Jun NH2-terminal kinase
(SAPK/JNK) and p38 MAPK. These inhibitors (JNK in-
hibitor II and SB202190, respectively) also abolishedactivated PPARβ/δ-dependent stimulation of LX-2 cell pro-
liferation (Figure 6E and 6F). This result identified two
main signaling pathways, SAPK/JNK and p38 MAPK,
which are involved in PPARβ/δ-induced HSC proliferation.
PPARβ/δ increased phosphorylation of the PI3K-dependent
PKCα/βII/MLK3 signaling pathway, which leads to p38 and
JNK MAPKs activation
Because the PI3K pathway appeared to be required for
PPARβ/δ-induced LX-2 cell proliferation, we analyzed the
phosphorylation level of the PI3K downstream target Akt,
a well-validated marker for PI3K activity. We observed a
PPARβ/δ-dependent increase in Akt phosphorylation on
serine 473 in control LX-2 cells (Figure 7A). This effect
was inhibited by the PI3K inhibitor LY294002 and was
blunted in PPARβ/δ KD LX-2 cells. Moreover, the Akt
protein expression level was not modified in control or
PPARβ/δ KD LX-2 cells. This indicated that Akt phos-
phorylation was both PPARβ/δ- and PI3K-dependent.
It is known that PI3K phosphorylation and stimulation
of PKC are among the earliest events in the activation of
MLK3, a MAPK kinase kinase (MAPKKK). MLK3 stimu-
lates the MAPKKs MKK3/6 and MKK4, which finally ac-
tivate p38 and JNK MAPKs in the last steps of initiating
HSC proliferation [19-22]. Among the different PKC iso-
forms tested in control LX-2 cells, GW501516 induced
only the phosphorylation of PKCα/βII on Thr638/641.
This phosphorylation was not observed in similarly trea-
ted PPARβ/δKD LX-2 cells (Figure 7B). In addition,
GW501516-activated PPARβ/δ had no effect on PKCα/
βII protein expression levels. Interestingly, GW501516
increased both MLK3 protein expression and phosphoryl-
ation specifically in control LX-2 cells (Figure 7C). This
effect was blunted by inhibitors of PI3K (LY294002) and
PKC (Gö6983). In line with these results, GW501516
treatment in control LX-2 cells induced a PPARβ/δ-
dependent phosphorylation of p38 at Thr180/Tyr182 and
JNK at Tyr183/Thr185 (Figure 7D). This effect was also
dependent on PI3K and PKC activation, as shown by
LY294002 and Gö6983 treatments, which abolished the
GW501516-induced phosphorylation of p38 and JNK
(Figure 7D).
Collectively, these results were consistent with our
data on HSC proliferation (Figure 6), and suggested that
GW501516 stimulated HSC proliferation by activating
p38 and JNK MAPKs, via an upstream signaling path-
way involving PI3K, PKCα/βII and MLK3 (Figure 7E).
Putative relevance of PPARβ/δ in human liver fibrosis
To test whether the activity of PPARβ/δ may also be
relevant to the development of human liver fibrosis,
its levels were measured in healthy subjects and
patients with alcoholic fibrosis/cirrhosis. In diseased
livers, there was a clear trend towards higher PPARβ/
Figure 5 Expression of PPARβ/δ and PPARβ/δ-dependent genes in LX-2 human hepatic stellate cells. Human LX-2 stellate cells were
serum-starved for 24 h, and then treated with DMSO (0.01%), 100nM GW501516, or 1μM GW501516 for 48 h. qRT-PCR analysis shows mRNA
levels of PDPK1, TGFβ1, TNF-α, MCP-1, Pro-COL1α1, Pro-COL3α1 and Desmin. Results are means ± SD of at least three independent experiments
performed in triplicate. * = p<0.05, Student's t-test.
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observed among fibrotic livers compared to healthy livers
(Figure 8A). This heterogeneity was observed for all the
mRNAs tested and may reflect differences in the severity
of fibrosis between diseased individuals. Importantly, two
well-established PPARβ/δ target genes, phosphoinositidedependent kinase 1 (PDPK1) and transforming growth
factor beta-1 (TGFβ1), showed increased expression in
diseased livers, which may reflect higher PPARβ/δ tran-
scriptional activity (Figure 8A). However, the expression of
PLIN2 and PDK4 was not increased (Figure 8A). Further-
more, the expression of inflammatory (MCP-1; Figure 8B)
Figure 6 PPARβ/δ controls pathways that regulate proliferation of LX-2 cells. Stable PPARβ/δ knockdown (KD) was performed by lentiviral
transduction of LX-2 cells with a siRNA against PPARβ/δ. Control LX-2 cells were transduced with the control vector. A) qRT-PCR showed reduced
PPARβ/δ expression in PPARβ/δ KD LX-2 cells. The control values were set to 1. Results are means ± SD of at least three independent experiments
performed in triplicate. B-F) Control and PPARβ/δ KD LX-2 cells were starved for 24 h in serum-free media and then treated for 48 h with DMSO
(control) or (B) 100 nM GW501516, or (C-F) 100 nM GW501516 in the presence or absence of 10 nM or 100 nM of (C) PD98059, (D) LY294002, (E)
JNK inhibitor II, or (F) SB202190. All inhibitors were added 30 min before GW501516 treatment. Cell proliferation was determined by [3H]-
thymidine incorporation. Values are expressed as a percentage of the values from DMSO-treated LX-2 cells, which were set to 100%. Values
represent means ± SEM from at least five independent experiments performed in triplicate; * = p<0.05 compared to DMSO-treated cells.
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significantly increased in the biopsy samples, in agree-
ment with results obtained in mouse liver. The expres-
sion of pro-COL3α1 and α-SMA showed a similar
trend, albeit without reaching statistical significance
(Figure 8C). Together, these results obtained from human
subjects suggest that a similar mechanism of fibrosis de-
velopment also exists in man, but a direct mechanisticimplication of PPARβ/δ in this species remains to be
substantiated.
Discussion/conclusion
This study identified GW501516-activated PPARβ/δ as
a promoter of uncontrolled liver repair, which results in
fibrosis, most likely via p38- and JNK-dependent stimu-
lation of HSC proliferation. This healing function of
Figure 7 PPARβ/δ induced a signaling pathway involving PI3K/PKCα/βII/MLK3/p38 and JNK MAPKs. Control and PPARβ/δ KD LX-2 cells
were serum-starved for 24 h, and then pre-treated with the indicated inhibitor for 30 min before incubation with 100 nM GW501516 or 0.01%
DMSO. After total cell lysis, proteins were resolved by immunoblot (IB).β-Tubulin served as the loading control. A) IB shows phosphorylation of
Akt on Ser473 in the presence or absence of PI3K inhibitor LY294002 (20 μM). B) IB shows PPARβ/δ-dependent
PKCα/βII protein expression and phosphorylation. C) IB shows MLK3 protein expression and phosphorylation with or without PI3K inhibitor
LY294002 (20 μM) or PKC inhibitor Gö6983 (7 μM). D) IB shows p38 and JNK protein expression and phosphorylation in the presence or absence
of LY294002 (20 μM) or Gö6983 (7 μM). IBs are representative of three independent experiments. E) Schematic model for the regulation of
human hepatic LX-2 stellate cell proliferation by GW501516-activated PPARβ/δ. Ligand activation of PPARβ/δ enhances PI3K activity, resulting in
activation of PKCα/βII and downstream MLK3. MLK3 signaling eventually results in increased phosphorylation of p38 and JNK MAPKs, which are
known to enhance HSC proliferation.
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ing [23]. Fibrosis is a response to a variety of chronic
damaging stimuli. It can cause an alteration in liver
structure that may lead to excessive deposition of ECM,apoptosis of hepatocytes and inflammation [2,3]. During
the fibrogenic response, activated HSCs proliferate and
indeed produce an excess of ECM and pro-inflammatory
proteins.
Figure 8 Expression of PPARβ/δ, PPARβ/δ target genes, inflammatory and fibrosis markers in human fibrotic livers. mRNA expression in
biopsies from healthy (n=8) and fibrotic (n=12) human livers is shown. qRT-PCR analysis shows PPARβ/δ mRNA expression, and mRNA expression
of the PPARβ/δ target genes PDPK1, TGFβ1, PLIN2 and PDK4 (A), the inflammatory marker MCP-1 (B), the fibrosis markers pro-COL1α1 and pro-
COL3α1 and the HSC marker α-SMA (C) * = p<0.05, Student's t-test.
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hepatic repair process, which often degenerates to liver
disease. In the present study, mice were exposed to
both CCl4 and a PPARβ/δ selective ligand for a long
period of time (i.e., 6 weeks). We found that agonist-
activated PPARβ/δ had an additive or synergistic effect
with CCl4 on the production of inflammatory cytokines,
pro-fibrotic ECM proteins and HSC markers, and on
the accumulation of hepatic triglycerides. In line with
our results, a recent study also demonstrated a profi-
brotic effect of the PPARβ/δ ligand GW501516 after
short-term CCl4 administration in mice [15]. In con-
trast to our data, this study did not identify the mo-
lecular mechanisms by which GW501516-activated
PPARβ/δ induced the fibrotic process. Furthermore, this
profibrotic action of activated PPARβ/δ was consistent
with our previous study in a rat model of acute CCl4-
induced liver injury treated with a different PPARβ/δ
ligand (L165041). In this model, we found increased
expression of Col1α1, α-SMA, and lysyl oxidase with
CCl4/L165041 treatment [10]. In contrast, other studies
concluded that GW0742- or KD3010-activated PPARβ/δ attenuated CCl4-induced hepatotoxicity [13,15]. Our
present findings suggest that CCl4 treatment alone
causes only a weak activation of PPARβ/δ. For example,
we showed that CCl4 did not result in important differ-
ences in the expression of several genes when wild type
and PPARβ/δ-null mice were compared, but
GW501516/CCl4 co-treatment strongly induced these
genes only in wild type mice. Importantly, we found
that several genes that were strongly stimulated by the
combined action of CCl4 and GW501516 were also
expressed at higher levels in hepatic tissue of patients
with confirmed alcohol-induced liver fibrosis/cirrhosis.
The discrepancies among different studies may be due
to differences in the ligands used, the dose applied, and
duration of administration. For instance, different
ligands may present different pharmacophore features
resulting in different physiological outcomes. In future
studies, it will be interesting to use cell type-specific de-
letion of PPARβ/δ in vivo to evaluate the individual
contribution of stellate cells, macrophages/Kupffer cells
and hepatocytes to the observed PPARβ/δ-dependent
profibrotic or protective effects.
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stimulation of HSC proliferation in vivo was unveiled in the
human LX-2 HSC line. These cells express key genes
involved in hepatic fibrosis [17]. Addition of the
GW501516 ligand activated PPARβ/δ in these cells and
increased proliferation after 48 h, whereas no change in
proliferation was observed in the PPARβ/δ KD cells. Simi-
lar to the in vivo results, the PPARβ/δ ligand also increased
the expression of pro-inflammatory and profibrotic factors.
These results were consistent with our previous study,
which showed that L165041-induced activation of
PPARβ/δ in cultured activated primary HSCs enhanced
proliferation and profibrotic factor expression [10].
In the present study, we also investigated genes that
were not direct targets of PPARβ/δ, but rather reflected
the activation of PPARβ/δ-dependent signaling path-
ways. We found that PPARβ/δ regulated the PI3K, p38
MAPK, and SAPK/JNK pathway, which is known to be
involved in cell proliferation. We also found that Erk1/2
MAPK and nuclear factor-κB (NF-κB) signaling did not
contribute to PPARβ/δ-induced HSC proliferation (data
not shown). In fact, it was previously shown that
MAPKs p38 and JNK were positive regulators of HSC
proliferation [1,24,25]. Those studies showed that mul-
tiple stress stimuli increased the activity of SAPK/JNK
and p38 MAPKs, which in turn activated several tran-
scription factors implicated in cell proliferation and dif-
ferentiation [26]. The present study revealed the novel
finding that, during fibrosis, these factors were regulated
by GW501516-activated PPARβ/δ. Thus, it was of inter-
est to unveil how PPARβ/δ controlled this paramount
signaling pathway.
Our results showed that GW501516-activated PPARβ/δ
enhanced phosphorylation of p38 and SAPK/JNK MAPKs
without changing their expression levels. This suggested
that PPARβ/δ was involved in the transcriptional regula-
tion of upstream kinases. In fact, PPARβ/δ-dependent
phosphorylation of p38 and JNK was suppressed by inhi-
bitors of PI3K (LY294002) and PKC (Gö6983). In
addition, we observed a PPARβ/δ-dependent phosphoryl-
ation of Akt at Ser473. Consistent with this finding,
ligand-activated PPARβ/δ in skin increased keratinocyte
survival upon exposure to stress through PI3K signaling;
this was reflected by increased Akt1 activity [27]. Interest-
ingly, PKCs are downstream targets of activated PI3K. It
was previously demonstrated that acetaldehyde induced
PKC activation, which then increased HSC proliferation
and activation [28-31] and collagen production [32,33].
Thus, we hypothesized that, in HSCs, PPARβ/δ might
also upregulate PDPK1 (Pdpk1) and downregulate phos-
phatase and tensin homolog (Pten) expression. This
would activate, via PI3K and PKC, the Ser/Thr protein
kinase MLK3, a cytokine-activated MAP3K known to
regulate JNK, p38, and Erk1/2 [21,34]. We showed forthe first time that GW501516 increased MLK3 protein
expression and phosphorylation in a PPARβ/δ-dependent
manner; furthermore, PKC inhibitors blocked MLK3 acti-
vation. Thus, GW501516 indirectly activated MLK3, a
downstream target of PKC. It was previously established
that MLK3 phosphorylates and activates the MAP2K iso-
forms MKK4/7 and MKK3/6, which then activate JNK
and p38, respectively [19,20,34,35]. Interestingly, because
GW501516 increased both the phosphorylation and ex-
pression levels of MLK3 (Figure 7C), MLK3 may be both
a direct and indirect target of activated PPARβ/δ. Recent
studies demonstrated that RNAi-mediated knockdown of
MLK3 inhibited serum-stimulated cell proliferation,
tumor cell proliferation, and growth factor/cytokine-
induced JNK, p38, and Erk1/2 activation [21,22]. These
cells also exhibited destabilized B-Raf/Raf1 complexes
[36]. Furthermore, CEP-1347, the small-molecule inhibi-
tor of all MLK members, caused reductions in pulmonary
fibrosis [37], pancreatitis [38], and neurodegeneration
[39] by inhibiting JNK activation.
In conclusion, this report is the first to show that
GW501516-activated PPARβ/δ could enhance both the
p38 and JNK MAPKs signaling pathways, and thus, in-
crease HSC proliferation in liver injuries. Furthermore, we
showed that PPARβ/δ activated p38 and JNK by phos-
phorylating PI3K/PKC/MLK3 components (Figure 7E).
We propose that activated PPARβ/δ increased HSC prolif-
eration, which then exacerbated inflammatory and fibrotic
processes during liver injuries. Taken together, these find-
ings showed that GW501516-activated PPARβ/δ repre-
sents an important regulatory step in HSC proliferation.
Finally, the role of PPARβ/δ and its activation in HSC pro-
liferation in liver fibrosis should be considered when
evaluating PPARβ/δ agonists as potential therapeutic
agents for broad applications; for example, a phase II clin-
ical trial is currently testing GW501516 as a treatment for
dyslipidemia. Furthermore, it will be important, in the fu-
ture, to evaluate whether natural ligands can achieve
effects similar to those of GW501516.
Materials and methods
Reagents
CCl4 was obtained from VWR International and olive oil
was from Sigma Aldrich. GW501516 was synthesized by
Kissei Pharmaceutical Co. Ltd. (Matshumoto, Japan).
CCl4 treatment of mice
Wild type and PPARβ/δ-null [23] 6–8 week-old male
mice of a mixed genetic background Sv129/C57BL/6,
were maintained at 23 °C on a 12-h light–dark cycle
with free access to water and a standard diet. To induce
liver fibrosis, 6 wild type and 6 PPARβ/δ-null mice
received repeated intraperitoneal injections (1 μl/g body
weight) of CCl4:olive oil (1:1) twice per week for 6 weeks.
Kostadinova et al. Cell & Bioscience 2012, 2:34 Page 13 of 16
http://www.cellandbioscience.com/content/2/1/34Injection of olive oil alone served as a control. In addition
to the CCl4-treatment, 6 wild type and 6 PPARβ/δ-null
male mice received 10 μg/kg/day of GW501516 in 0.5%
carboxymethyl cellulose (CMC), or GW501516 and CMC
alone by gavage once per day for 6 weeks. At the end of
the experimental period, blood samples were collected by
retro-orbital puncture for measurement of the liver dam-
age specific enzyme alanine transaminase (ALT) and neu-
tral lipid analysis and the mice were then killed by cervical
dislocation. After weighing, livers were either rapidly
frozen in liquid nitrogen for later analyses or imme-
diately prepared for immunocytochemistry studies
and pathological examinations. All treatments were
repeated in 3 independent experiments (n=6/geno-
type). All experiments involving animals were
approved by the Veterinary Office of the Canton
Vaud (Switzerland) in accordance with the Federal
Swiss Veterinary Office Guidelines and conformed to
the European Commission Directive 86/609/EEC and
the “Guide for the Care and Use of Laboratory Ani-
mals” (NIH publication 86–23 revised 1985).
Neutral lipid analysis
Hepatic lipids were determined by gas chromatography
[40].
Patients and biopsies
Liver biopsies were collected by transparietal puncture
from 8 healthy individuals and 12 patients (10 males, 2
females; aged 48–69 years) with alcohol-caused liver fi-
brosis or cirrhosis, diagnosed on clinical, biological, and
histological grounds [41]. Total RNA was isolated from
the liver biopsies with TRIzol reagent (Invitrogen, Carlsbad,
CA) and gene transcription was analyzed by quantitative
reverse-transcription PCR. All clinical investigations were
conducted according to the principles expressed in the
Declaration of Helsinki.
Total RNA isolation, reverse transcription PCR (RT-PCR),
and qRT-PCR
Total RNA was extracted from frozen mouse liver sam-
ples, from human liver biopsies, or from LX-2 cells with
TRIzol reagent (Invitrogen), according to the manufac-
turer’s instructions. Single-stranded cDNA templates were
generated by reverse transcription with Superscript II
reverse transcriptase (Invitrogen). For qRT-PCR (TAQ
MAN), the cDNA equivalent of 10 ng of total RNA
was amplified. All primers, including those specific
for amplifying mRNA of mouse or human PPARβ/δ,
PPARα, PPARγ TNF-α, MCP-1, MIP-1α, TGF-β1, PDGFBB,
pro-Col1α1, pro-Col3α1, α-SMA, Desmin, PDPK1, and
PDK4, were purchased from Applied Biosystems.
Fluorescence was quantified with an ABI Prism 7900HT
SDS system (Applied Biosystems). The followinghousekeeping genes were used to normalize mouse liver
samples: Eef1A1, mRps9, mGapdh; human biopsies:
RPS18, hTBP; and LX-2 cells: hGUSB. Relative mRNA
expression levels were calculated with the comparative
Ct method (User Bulletin # 2, Applied Biosystems) and
qBase software. All values represent means from treated
samples compared to means from control samples (ve-
hicle- or olive oil-treated wild type mice or DMSO-
treated LX-2 cells), which were set to 1.Histological analysis and Sirus Red staining
Liver specimens were fixed in 4% paraformaldehyde
(PAF) for 24 h, and then embedded in paraffin. Tissues
sections (4 μm) were stained with hematoxylin/eosin
(H/E), for routine examination, or with Sirus Red for
Col1α1 and Col3α1 visualization.Liver pathology
To determine the degree of necroinflammatory liver injury,
mouse liver sections were submitted to blind histopatholo-
gic examinations (grading according to Ischak’s score) by
an independent pathologist (see Acknowledgements).LX-2 cells stimulation by GW501516 and Western blot
analysis
When indicated, control and LX-2 cells treated with
siRNA against PPARβ/δ were first pre-incubated for 30
min in serum-free media with 20μM LY294002 (PI3K in-
hibitor) or 7 nM Gö6983 (PKC inhibitor, Calbiochem)
before the addition of GW501516 for 24 h. Total cell
proteins were extracted in ice-cold lysis buffer (10 mM
Tris–HCl pH 7.5, 150 mM NaCl, 5 mM NaF, 1% Triton
X-100, 0.1% SDS) supplemented with the following pro-
tease inhibitors: 2 μg/ml Aprotinin, 1 μg/ml Leupeptin,
2 μg/ml Pepstatin A, 1 mM phenylmethylsulfonyl fluor-
ide, 1% deoxycholic acid, and 1 mM Na3VO4. After
quantification, 30 μg of proteins were separated by
SDS-PAGE and subjected to immunoblotting. All primary
antibodies were diluted at 1/1000 and incubated overnight
in 1× TBS 0.1% Tween-20, 5% nonfat milk. Anti-phospho
Akt (Ser473), anti-phospho PKCα/βII (Thr638/641), anti-
phospho MLK3 (Thr277/Ser281), anti-phospho p38 MAPK
(Thr180/Tyr182), anti-phospho JNK/SAPK (Tyr183/Tyr185),
anti-Akt, anti-PKCα, anti-MLK3, anti-p38 MAPK, and
anti-SAPK/JNK were from Cell Signaling; anti-β-tubulin
(loading control) was from BD PharmingenTM. The sig-
nals were detected with an ECL detection kit (Amersham
Pharmacia Biotech), according to the manufacturer's
instructions. The ScanImage densitometry program was
used for quantification, and signals were normalized to
the β-tubulin signal.
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Control LX-2 and PPARβ/δ KD LX-2 cells were plated
in 24-well culture plates at a seeding density of 3×104
and incubated in DMEM with 2% FCS. One day later,
they received serum-free medium for 24 h. Thereafter,
they were treated with 0.01% DMSO (control), or 100
nM GW501516 for 48 h in serum-free medium. Alterna-
tively, cells were pre-incubated for 30 min with 10 nM
or 100 nM of SB202190 (p38 MAPK inhibitor), JNK in-
hibitor II, LY294002 (PI3K inhibitor), or PD98059
(MEK1 inhibitor) before the addition of 100 nM
GW501516 for 48 h in serum-free medium. During the
last 13 h of these treatments, 1 μCi/well of [3H-methyl]-
thymidine was added. Then, the culture media were dis-
carded, plates were placed on ice, cells were washed with
ice-cold PBS, and then fixed in 500 μl ice-cold 10%
trichloroacetic acid (TCA) for 20 min. TCA was
removed, and 100 μl cell dissociation solution (0.2M
NaOH, 1% SDS) was added to each well. Cells were
incubated with gentle shaking for 10 min at room
temperature. The samples were neutralized with 100 μl
of 0.2 M HCl and transferred to vials with 3 ml scintilla-
tion cocktail. The scintillation counts (cpm) for treated
control LX-2 cells and PPARβ/δ KD LX-2 cells were
expressed as a percentage of the counts measured for
the DMSO treated LX-2 cells, which were set to 100%.
Measurements of hepatic MCP-1 and MIP-1 protein
expression
Simultaneous quantifications of MCP-1 and MIP-1a
levels in the livers of treated wild type and PPARβ/δ-null
mice were performed with the mouse cytokine/chemo-
kine LINCOplex KIT, 96-well plate assay (LINKO Re-
search, MCYTO-70K) on a LuminexR100. Similar sized
pieces of frozen liver samples were homogenized with a
power homogenizer (Polytron) in 1 ml of ice-cold PBS
with the complete protease inhibitor cocktail. Lysates
were incubated on ice for 10 min, followed by centrifu-
gation at 13,000 rpm for 20 min at 4 °C. Supernatants
were collected, and centrifugation was repeated several
times, until the sample was clear of debris. The isolated
proteins were quantified with the Bradford assay
(BioRad). An immunoassay was run with 25 μl protein
lysate to determine the cytokine/chemokine levels (pg/
ml) in the liver according to the manufacturer’s instruc-
tions. All data were normalized to the protein concen-
tration, and values were expressed relative to the value
measured in vehicle-treated (olive oil) wild type mice,
which was set to 1 (n=6 for each treated group).
Immunohistochemistry
To detect proliferating and activated HSCs, paraffin-
embedded liver sections (4 μm) were double immunos-
tained with the anti-αSMA antibody, as a marker foractivated hepatic stellate cells, and anti-Ki67, as a mar-
ker for cell proliferation. Briefly, after deparaffinization,
the antigen unmasking step was performed in 0.01 M
citrate buffer, pH 6.0, by heating sections to 100 °C in a
microwave oven for 20 min. After washing, sections
were blocked in 1% BSA/1×PBS for 30 min at room
temperature, and then incubated overnight at 4 °C with
mouse anti-α-SMA (1:50) and rabbit anti-Ki67 (1:100) or
with anti-F4/80 (1:10) antibody in blocking buffer. After
washing, slides were incubated with the appropriate sec-
ondary antibodies for 40 min in blocking buffer. Second-
ary antibodies were anti-mouse IgG Cy3 (1:100) and
anti-rabbit IgG FITC (1:400) for anti-α SMA/anti-Ki67,
or anti-rat A568 (1:200) for anti-F4/80. After washing 3
times, slides were incubated for 5 min in DAPI for nu-
clear staining. Then, the sections were rinsed in water
and mounted with DABCO for confocal-microscopy.
Knockdown of PPARβ/δ in LX-2 cells by lentiviral infection
The following sequence was chosen to target the mouse
PPARβ/δ sequence: 5'-GCACATCTACAACGCCTAC-3'.
This sequence was 100% identical to the human PPARβ/δ
sequence. A BLAST search ensured that the sequences
would not target other RNAs in a nonspecific manner.
The short interfering RNA (siRNA) was cloned into a
pLV-TH lentivirus vector under the control of the poly-
merase III-dependent H1 promoter [42]. In addition, an
internal cassette allowed expression of the green fluores-
cent protein (GFP) marker gene under the control of the
elongation factor (EF-1) α promoter [43]. In our study,
the empty pLV-TH vector, which contained all the fea-
tures, but not the siRNA, was designated the control, and
the pLV-TH vector containing PPARβ/δ siRNA was
designated psiPPARβ/δ. All recombinant lentiviruses were
produced by transient transfection of 293T cells according
to standard protocols. Briefly, subconfluent 293T cells
were co-transfected with 20 μg of the control vector,
pLV-TH, or the PPARβ/δ-targeted vector, psiPPARβ/δ, 15
μg of pCMV-ΔR8.91, and 5 μg of pMD2G-VSVG by cal-
cium phosphate precipitation. The medium was changed
after 16 h, and the recombinant lentiviruses were har-
vested 24 h later. The lentiviral infection efficiency in
LX2 cells was monitored by the percentage of GFP-
expressing cells detected by FACS analysis. At an infec-
tion multiplicity of 60, 90% of the LX-2 cells expressed
GFP 48 h after transduction. The infected cells were then
harvested, and total RNA was extracted. A qRT-PCR ana-
lysis demonstrated that PPARβ/δ was knocked down
(KD) by 90% in the PPARβ/δ KD LX-2 cells compared to
control-infected LX-2 cells (Figure 7A).
Statistical analysis
Data are expressed as means ± SEM or SD for treated
wild type and PPARβ/δ-null mice (n=6), or as the means
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formed in triplicate for LX-2 cells. Statistical significance
was determined with the Student's t-test.
Additional file
Additional file 1: Supporting Figure 1. Effect of CCl4 and CCl4/
GW501516 treatment on Pparα and Pparγ expression in mouse liver.
Supporting Figure 2. Quantification of Sirus Red staining in mouse liver
sections.
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